Register now for Fin24 Dashboard and get access to portfolios, watchlists, financial comparison tools, and a whole lot more to help you achieve your financial goals.

Data provided by McGregor BFA
All data is delayed
Loading...
Where am I? Home
 
Prices are delayed by 15min.
Join the Fin24.com conversation about JSE-listed stock by using every time you tweet.

SA drives Aspen growth

Mar 03 2010 14:16 Andile Makholwa

Company Data

Aspen [JSE : APN]

Last traded R100.60
Change R-0.57
% Change -0.56%
Cumulative volume 779,310
Market cap R43.92bn

Last Updated: 10/02/2012 at 19:33. Prices are delayed by 15 minutes. Source: McGregor BFA

 

Related Articles

Aspen Pharmacare stocks jump

SA ops to boost Aspen

Aspen in TB deal with Eli Lilly

Glaxo, Aspen tie up deal

Aids drugs boost Aspen

International ops to boost Aspen

 

Top Stories

Financial mess 'unintended', says Nedbank

Feb 12 2012 15:59

Moral hazard, financial weapons of mass destruction, a huge mess - these were the words used by a founder member to sum up the collapse of the Pinnacle Point Group.

Construction looks to more graft

Feb 12 2012 15:58

Construction companies are now undertaking a second round of self-examination into uncompetitive behaviour.

Merkel 'taking Europe in wrong direction'

Feb 12 2012 14:54

American billionaire George Soros has slammed German Chancellor Angela Merkel, warning that her policies could lead to a repeat of the Great Depression.

 
Share Share line Print

Johannesburg - Pharmaceutical group Aspen Pharmacare Holdings [JSE:APN] on Wednesday reported a 31% rise in after tax profit for the interim period to end-December.

The group's revenue grew by 10% to R4.576bn, while headline earnings per share from continuing operations increased 27% to 242.3 cents.

The group said its South African business maintained its leadership position across the private and public sectors of the pharmaceutical market and grew revenue by 23% to R2.55bn, while revenue from offshore operations increased by 12% to R1.797bn.

Aspen CEO Stephen Saad said "the excellent performance" recorded by the South African operations was driven by robust volume growth and margin improvements.

"Revenue growth in the international business is attributed to gains from global brands, the Asia Pacific domestic brands, the oncology business and from the GlaxoSmithKline (GSK) transactions."

- Fin24.com

 
 
Comment on this story
0 comments
Add your comment
Comment 0 characters remaining
Facebook still a closed book in China
Feb 08 2012 16:59

Mark Zuckerberg wants to ''friend'' China's massive market but how far is he prepared to go, and against what competition?

Attie

Whilst doing my regular book browsing at Exclusive Books just before Christmas 2011 a book with the simple title “My Book” caught my eye. Paging through the book I saw nothing else but wild life photographs with accompanying quotations by either the author or another well-known person. ... Read their blog...

Recently updated
Podcasts
The Sishen saga

Legal expert Peter Leon on the increasingly complex legal wrangle over the Sishen Iron Ore mine. Time: 8:17 Listen Here...

Before you list

Is the clarion call of the JSE calling? Listen to Fin24’s expert panel discussion before you list your small business. Time: 17:29

Compare and Buy

Compare and apply for hundreds of financial products from many suppliers.

Credit cards Medical aid Current accounts Think Money

Money Clinic

Money Clinic Do you have a question about your finances? We'll get an expert opinion.
Click here...

Loading...